Infectious Diseases Chronic Diseases Treatment Options Diabetes Patient Care Treatment Chronic Illness Hypertension Diagnosis Patient Recovery Alzheimer's Treatment Early Detection Cardiovascular Diseases Neurological Disease Management Treatment Protocols Cancer Kidney Disease Treatment Alzheimer's Disease Antibiotic Treatment Infectious Disease Control Cancer Treatment Progression-Free Survival Testing Liver Diseases Epidemiology Risk Factors Antibiotics Pandemic Response Technology in Healthcare Hypertension Care Diagnostics Patient Outcomes Mortality Rates Drug Resistance Metabolic Disorders Chagas Disease Treatment Personalized Medicine Surveillance Chronic Illnesses Dengue Chronic Illness Management Long Covid Eosinophilic Conditions Emerging Diseases Patient Education Contagious Diseases Intensive Care Pharmacological Treatment Chagas Disease Virus Outbreaks Cancer Screening Dementia Care Alzheimer's Care Common Colds Inflammatory Bowel Disease Flu Treatment B Cell Therapies At-Risk Populations Cancer Care Hospital Protocols Dementia Diabetes Control Stroke Programs Lung Conditions Viral Infections Communicable Diseases Antifungal Treatments Antifungal Therapy Blood Cancers Outbreaks Stroke Supportive Care Influenza Public Health Hospitalization Rates Treatment Development Cognitive Disorders Quad-demic Idiopathic Pulmonary Fibrosis Infection Control Severe Acute Respiratory Infection Antiviral Treatments COVID-19 HIV Testing Hospitalization HIV Treatment Vasculitis Bacterial Infections Multidrug-Resistant Tuberculosis Risk Assessment Genetic Disorders Support Systems Sickle Cell Disease
The agency says donor retrenchment following the U.S. withdrawal has forced a leaner, hyper‑prioritised response.
